Preparation and Preliminary Evaluation of Para-[F-18]Fluorofenbufen Octylamide as a Novel PET Imaging Agent for Brain Tumor

摘要

Introduction: At present, there are more than 90,000 new cases of cancer each year in Taiwan, of which about 1,000 to 2,000 are primary malignant brain tumors. Treatment of brain tumors is rather tricky and the prognosis of treatment is rather poor and the average survival is only 14 months. Therefore, early classification and judgment of brain tumor play a very important role in the choice of treatment methods. The cyclooxygenase-2 (COX-2) enzyme is usually used as a target for cancer therapy. Studies have shown that COX-2 expression is significantly different between low-grade and high-grade brain tumors (p < 0.01). This study has developed the fluoro-fenbufen derivative; furthermore, by using positron emission tomography (PET) imaging technique is to investigate the animal distribution of the drug.